Sunil J Wimalawansa

List of Publications by Year
in descending order

178	8,932	50566	53065
papers	citations	48 h-index	89 g-index

185	185	185	7530
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Vitamin D: A single initial dose is not bogus if followed by an appropriate maintenance intake. JBMR Plus, 2022, 6, e10606.	1.3	3
2	Health Risk Assessment From Heavy Metals Derived From Drinking Water and Rice, and Correlation With CKDu. Frontiers in Water, 2022, 3, .	1.0	4
3	The emerging evidence for non-skeletal health benefits of vitamin D supplementation in adults. Nature Reviews Endocrinology, 2022, 18, 323-323.	4.3	12
4	CaPO4-Mediated CKD of Crystallo-Tubular-Nephropathy [CKD-CTN]â€"A Crystal and Nanotube-Induced Geo-Environmental Disease. Frontiers in Water, 2022, 4, .	1.0	1
5	Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19. Virus Research, 2021, 292, 198235.	1.1	97
6	Targeting Nitric Oxide for Bone Disease. , 2020, , 666-696.		2
7	Molecular and cellular toxicity of fluoride in mystery, tubulointerstitial chronic kidney disease: a systematic review. Reviews in Environmental Science and Biotechnology, 2020, 19, 117-147.	3.9	12
8	Renal tubular lysosomal vacuoles are a generic toxic manifestation and not particularly associated withÂagrochemicals andÂheavy metal toxicity orÂspecific to a disease. Kidney International, 2020, 97, 1058.	2.6	5
9	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosisâ€"2020 Update. Endocrine Practice, 2020, 26, 1-46.	1.1	493
10	Factors Affecting the Environmentally Induced, Chronic Kidney Disease of Unknown Aetiology in Dry Zonal Regions in Tropical Countriesâ€"Novel Findings. Environments - MDPI, 2020, 7, 2.	1.5	16
11	Does fluoride cause the mysterious chronic kidney disease of multifactorial origin?. Environmental Geochemistry and Health, 2020, 42, 3035-3057.	1.8	16
12	Association between body mass index and estimated glomerular filtration rate in patients with chronic kidney disease of unknown aetiology in Sri Lanka. Environmental Geochemistry and Health, 2020, 42, 2645-2653.	1.8	6
13	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSISâ€"2020 UPDATE EXECUTIVE SUMMARY. Endocrine Practice, 2020, , .	1.1	1
14	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosisâ€" 2020 Update Executive Summary. Endocrine Practice, 2020, 26, 564-570.	1.1	108
15	Procalcitonin as a biomarker for critically ill patients with sepsis: Effects of vitamin D supplementation. Journal of Steroid Biochemistry and Molecular Biology, 2019, 193, 105428.	1.2	12
16	Public health interventions for chronic diseases: costâ€“benefit modelizations for eradicating chronic kidney disease of multifactorial origin (CKDmfo/ CKDu) from tropical countries. Heliyon, 2019, 5, e02309.	1.4	16
17	Vitamin D Deficiency: Effects on Oxidative Stress, Epigenetics, Gene Regulation, and Aging. Biology, 2019, 8, 30.	1.3	206
18	There is no evidence that organochlorine pesticides, such as DDT, cause chronic kidney disease of unknown etiology. Science of the Total Environment, 2019, 649, 1636-1637.	3.9	2

#	Article	IF	Citations
19	Improving Lives Through Alleviating Malnutrition. , 2019, , 293-304.		0
20	Disease prevention strategies using vitamin D. Advances in Health and Behavior, 2019, 2, 96-100.	0.1	1
21	Efficacy of different modes of vitamin D supplementation strategies in Saudi adolescents. Journal of Steroid Biochemistry and Molecular Biology, 2018, 180, 23-28.	1.2	11
22	Calcium and vitamin D in human health: Hype or real?. Journal of Steroid Biochemistry and Molecular Biology, 2018, 180, 4-14.	1.2	71
23	Vitamin D: Effects on human reproduction, pregnancy, and fetal well-being. Journal of Steroid Biochemistry and Molecular Biology, 2018, 180, 41-50.	1.2	49
24	Non-musculoskeletal benefits of vitamin D. Journal of Steroid Biochemistry and Molecular Biology, 2018, 175, 60-81.	1.2	112
25	Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome. Journal of Steroid Biochemistry and Molecular Biology, 2018, 175, 177-189.	1.2	195
26	Clinical practice guidelines for vitamin D in the United Arab Emirates. Journal of Steroid Biochemistry and Molecular Biology, 2018, 175, 4-11.	1.2	67
27	Vitamin D and cardiovascular diseases: Causality. Journal of Steroid Biochemistry and Molecular Biology, 2018, 175, 29-43.	1.2	65
28	Highlights from the 5th International Conference on Vitamin D Deficiency, Nutrition and Human Health, Abu Dhabi, United Arab Emirates, March 24â€“25, 2016. Journal of Steroid Biochemistry and Molecular Biology, 2018, 175, 1-3.	1.2	4
29	Vitamin D status among the juvenile population: A retrospective study. Journal of Steroid Biochemistry and Molecular Biology, 2018, 175, 49-54.	1.2	9
30	Vitamin D supplementation guidelines. Journal of Steroid Biochemistry and Molecular Biology, 2018, 175, 125-135.	1.2	454
31	Physiology of Calcitonin and Its Therapeutic Uses. , 2018, , 178-191.		1
32	Highlights from the 6 th International Conference on Vitamin D Deficiency, â€œNutrition and Human Healthâ€, Abu Dhabi, United Arab Emirates, March 9-10, 2017. Journal of Steroid Biochemistry and Molecular Biology, 2018, 180, 1-3.	1.2	2
33	Acronyms, CINAC, ACN, KDUCAL or NUCAL and so on are inappropriate to use for describing CKDu. Journal of Epidemiology and Community Health, 2018, 72, 967-968.	2.0	7
34	Vitamin D Deficiency Prevalence and Predictors in Early Pregnancy among Arab Women. Nutrients, 2018, 10, 489.	1.7	33
35	Vitamin D Adequacy and Improvements of Comorbidities in Persons with Intellectual Developmental Disabilities. Journal of Childhood & Developmental Disorders, 2016, 2, .	0.3	10
36	High Prevalence of Vitamin D Deficiency in Cambodian Women: A Common Deficiency in a Sunny Country. Nutrients, 2016, 8, 290.	1.7	24

#	Article	IF	Citations
37	American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis â€" 2016--Executive Summary. Endocrine Practice, 2016, 22, 1111-1118.	1.1	453
38	American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis â€" 2016. Endocrine Practice, 2016, 22, 1-42.	1.1	377
39	Endocrinological Mechanisms of Depressive Disorders and Ill Health. Expert Review of Endocrinology and Metabolism, 2016, 11, 3-6.	1.2	0
40	Environmentally induced, occupational diseases with emphasis on chronic kidney disease of multifactorial origin affecting tropical countries. Annals of Occupational and Environmental Medicine, 2016, 28, 33.	0.3	27
41	Optimum duration and safety of long-term use of potent anti-resorptive medications in osteoporosis. Expert Review of Endocrinology and Metabolism, 2016, 11, 329-348.	1.2	2
42	The role of ions, heavy metals, fluoride, and agrochemicals: critical evaluation of potential aetiological factors of chronic kidney disease of multifactorial origin (CKDmfo/CKDu) and recommendations for its eradication. Environmental Geochemistry and Health, 2016, 38, 639-678.	1.8	86
43	Vitamin D Deficiency is a Surrogate Marker for Visceral Fat Content, Metabolic Syndrome, Type 2 Diabetes, and Future Metabolic Complications. Journal of Diabetes, Metabolic Disorders & Control, 2016, 3, .	0.2	11
44	Effect of Water Hardness on Non-Communicable Diseases, Including Chronic Kidney Disease of Multifactorial Origin (CKDmfo/CKDuo). Journal of Environment and Health Sciences, 2016, 2, 1-11.	1.0	11
45	Preventing Long-Term Complications of Obesity, Type 2 Diabetes, and Metabolic Syndrome. Endocrinology & Metabolic Syndrome: Current Research, 2015, 04, .	0.3	1
46	Emphasizing the Health Benefits of Vitamin D for Those with Neurodevelopmental Disorders and Intellectual Disabilities. Nutrients, 2015, 7, 1538-1564.	1.7	45
47	Escalating chronic kidney diseases of multi-factorial origin (CKD-mfo) in Sri Lanka: causes, solutions, and recommendationsâ€"update and responses. Environmental Health and Preventive Medicine, 2015, 20, 152-157.	1.4	22
48	Pheochromocytoma and Paraganglioma. Endocrine Practice, 2015, 21, 406-412.	1.1	54
49	Obesity and Type 2 Diabetes: Preventing Associated Complications. Journal of Diabetes, Metabolic Disorders & Control, 2015, 2, .	0.2	2
50	In the Era of Budgetary Constraints, Cost-Effective Management of Metabolic Syndrome, Type 2 Diabetes, and Obesity is Essential. Current Research in Diabetes & Obesity Journal, 2015, 1, .	0.1	1
51	Escalating chronic kidney diseases of multi-factorial origin in Sri Lanka: causes, solutions, and recommendations. Environmental Health and Preventive Medicine, 2014, 19, 375-394.	1.4	65
52	Stigma of obesity: A major barrier to overcome. Journal of Clinical and Translational Endocrinology, 2014, 1, 73-76.	1.0	13
53	Mechanisms of Developing Post-Traumatic Stress Disorder: New Targets for Drug Development and Other Potential Interventions. CNS and Neurological Disorders - Drug Targets, 2014, 13, 807-816.	0.8	17
54	Visceral adiposity and cardiometabolic risks: epidemic of abdominal obesity in North America. Research and Reports in Endocrine Disorders, 2013, , 17.	0.4	4

#	Article	IF	Citations
55	Thermogenesis-based interventions for obesity and Type 2 diabetes mellitus. Expert Review of Endocrinology and Metabolism, 2013, 8, 275-288.	1.2	4
56	Causes and Risk Factors for Post-Traumatic Stress Disorder: The Importance of Right Diagnosis and Treatment. Asian Journal of Medical Sciences, 2013, 5, 1-13.	0.0	6
57	Food Fortification Programs to Alleviate Micronutrient Deficiencies. Journal of Food Processing & Technology, 2013, 04, .	0.2	19
58	Vitamin D, Fractures, and Human Skeletal Health. Journal of Clinical Densitometry, 2012, 15, 503.	0.5	0
59	Vitamin D in the New Millennium. Current Osteoporosis Reports, 2012, 10, 4-15.	1.5	87
60	Vitamin D: what clinicians need to know. Sri Lanka Journal of Diabetes Endocrinology and Metabolism, 2012, 2, 73.	0.1	14
61	Dietary, Lifestyle, Medical, and Stressâ€Relief Choices in Promoting Health. FASEB Journal, 2012, 26, 377.2.	0.2	0
62	Vitamin D: an essential component for skeletal health. Annals of the New York Academy of Sciences, 2011, 1240, E1-12.	1.8	19
63	Nitric oxide and bone. Annals of the New York Academy of Sciences, 2010, 1192, 391-403.	1.8	95
64	Calcitonin. , 2010, , 653-666.		4
65	Transdermal Nitroglycerin Therapy May Not Prevent Early Postmenopausal Bone Loss. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3356-3364.	1.8	47
66	EFFECTS OF FRUITS AND VEGETABLES ON BONES. Acta Horticulturae, 2009, , 421-434.	0.1	0
67	Nitric oxide: new evidence for novel therapeutic indications. Expert Opinion on Pharmacotherapy, 2008, 9, 1935-1954.	0.9	53
68	Nitric oxide: novel therapy for osteoporosis. Expert Opinion on Pharmacotherapy, 2008, 9, 3025-3044.	0.9	54
69	Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opinion on Drug Safety, 2008, 7, 491-512.	1.0	39
70	Bisphosphonate-Associated Osteomyelitis of the Jaw: Guidelines for Practicing Clinicians. Endocrine Practice, 2008, 14, 1150-1168.	1.1	13
71	Skeletal Effects of Nitric Oxide. , 2008, , 1273-1310.		2
72	Rationale for Using Nitric Oxide Donor Therapy for Prevention of Bone Loss and Treatment of Osteoporosis in Humans. Annals of the New York Academy of Sciences, 2007, 1117, 283-297.	1.8	57

#	Article	IF	Citations
73	Novel Targets and Therapeutics for Bone Loss. Annals of the New York Academy of Sciences, 2006, 1068, 402-409.	1.8	13
74	The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study. Osteoporosis International, 2005, 16, 631-635.	1.3	79
75	Testing Two Predictions for Fracture Load Using Computer Models of Trabecular Bone. Biophysical Journal, 2005, 89, 759-767.	0.2	13
76	Adrenomedullin Antagonist Treatment During Early Gestation in Rats Causes Fetoplacental Growth Restriction Through Apoptosis1. Biology of Reproduction, 2004, 71, 1475-1483.	1.2	30
77	Mesenteric Arterial Relaxation to Calcitonin Gene-Related Peptide Is Increased During Pregnancy and by Sex Steroid Hormones1. Biology of Reproduction, 2004, 71, 1739-1745.	1.2	27
78	Studies on the Effects of the N-Terminal Domain Antibodies of Calcitonin Receptor-Like Receptor and Receptor Activityâ€“Modifying Protein 1 on Calcitonin Gene-Related Peptide-Induced Vasorelaxation in Rat Uterine Artery1. Biology of Reproduction, 2004, 70, 1658-1663.	1.2	16
79	Female Sex Steroid Hormones and Pregnancy Regulate Receptors for Calcitonin Gene-Related Peptide in Rat Mesenteric Arteries, but Not in Aorta1. Biology of Reproduction, 2004, 70, 1055-1062.	1.2	34
80	An expression relating breaking stress and density of trabecular bone. Journal of Biomechanics, 2004, 37, 1241-1249.	0.9	21
81	Calcitonin, Overview. , 2004, , 436-443.		0
82	NK1, NK2, NK3 and CGRP1 receptors identified in rat oral soft tissues, and in bone and dental hard tissue cells. Cell and Tissue Research, 2003, 311, 383-391.	1.5	34
83	Effects of steroid hormones on calcitonin gene-related peptide receptors in cultured human myometrium. American Journal of Obstetrics and Gynecology, 2003, 188, 466-472.	0.7	6
84	CGRP1 and NK1 receptors in postnatal, developing rat dental tissues. European Journal of Oral Sciences, 2003, 111, 497-502.	0.7	12
85	Evidence for the existence of a new receptor for CGRP, which is not CRLR. Peptides, 2003, 24, 65-71.	1.2	28
86	Specific N-terminal CGRP fragments mitigate chronic hypoxic pulmonary hypertension in rats. Regulatory Peptides, 2003, 110, 93-99.	1.9	11
87	CGRP receptor heterogeneity: a role for receptor component protein?. Trends in Endocrinology and Metabolism, 2003, 14, 4-6.	3.1	0
88	Mechanisms Involved in Calcitonin Gene-Related Peptide-Induced Relaxation in Pregnant Rat Uterine Artery1. Biology of Reproduction, 2003, 69, 1635-1641.	1.2	30
89	Adrenomedullin Requires an Intact Nitric Oxide System to Function as an Endogenous Vasodilator in Rat Gestation. Hypertension in Pregnancy, 2003, 22, 9-24.	0.5	15
90	Model for Bone Strength and Osteoporotic Fractures. Physical Review Letters, 2002, 88, 068101.	2.9	26

#	Article	IF	Citations
91	Infusion of Pregnant Rats with Calcitonin Gene-Related Peptide (CGRP)8-37, a CGRP Receptor Antagonist, Increases Blood Pressure and Fetal Mortality and Decreases Fetal Growth1. Biology of Reproduction, 2002, 67, 624-629.	1.2	37
92	Effects of Pregnancy and Female Sex Steroid Hormones on Calcitonin Gene-Related Peptide Content of Mesenteric Artery in Rats1. Biology of Reproduction, 2002, 67, 1430-1434.	1.2	9
93	Placental and Fetal Growth and Development in Late Rat Gestation Is Dependent on Adrenomedullin1. Biology of Reproduction, 2002, 67, 1025-1031.	1.2	59
94	Sex Steroid Hormones Enhance Hypotensive Effects of Calcitonin Gene-Related Peptide in Aged Female Rats1. Biology of Reproduction, 2002, 67, 1881-1887.	1.2	15
95	Calcitonin gene-related peptide in pregnancy and its emerging receptor heterogeneity. Trends in Endocrinology and Metabolism, 2002, 13, 263-269.	3.1	59
96	Expression and Regulation of Calcitonin Gene-Related Peptide Receptor in Rat Placentas1. Biology of Reproduction, 2002, 67, 1321-1326.	1.2	15
97	A model of trabecular bone and an application to osteoporosis. Physica A: Statistical Mechanics and Its Applications, 2002, 315, 98-104.	1.2	3
98	Arthritic calcitonin/Î± calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain, 2001, 89, 265-273.	2.0	145
99	Calcitonin gene- and parathyroid hormone-related peptides in preeclampsia: effects of magnesium sulfate. Obstetrics and Gynecology, 2001, 97, 893-897.	1.2	24
100	Blood Pressure and Cardiovascular Tone: Role of CGRP Family of Peptides. Scientific World Journal, The, 2001, 1, 32-32.	0.8	5
101	Distribution of Amylin-Immunoreactive Neurons in the Monkey Hypothalamus and their Relationships with the Histaminergic System.. Archives of Histology and Cytology, 2001, 64, 295-303.	0.2	21
102	Calcitonin Gene- and Parathyroid Hormone-Related Peptides in Preeclampsia. Obstetrics and Gynecology, 2001, 97, 893-897.	1.2	13
103	Pregnancy and Steroid Hormones Enhance the Systemic and Regional Hemodynamic Effects of Calcitonin Gene-Related Peptide in Rats1. Biology of Reproduction, 2001, 64, 1776-1783.	1.2	29
104	Nitroglycerin Therapy Is as Efficacious as Standard Estrogen Replacement Therapy (Premarin) in Prevention of Oophorectomy-Induced Bone Loss: A Human Pilot Clinical Study. Journal of Bone and Mineral Research, 2000, 15, 2240-2244.	3.1	97
105	Frequency-Dependent Effect of Nitric Oxide Donor Nitroglycerin on Bone. Journal of Bone and Mineral Research, 2000, 15, 1119-1125.	3.1	50
106	Restoration of Ovariectomy-Induced Osteopenia by Nitroglycerin. Calcified Tissue International, 2000, 66, 56-60.	1.5	46
107	Pregnancy and sex steroid hormones enhance circulating calcitonin gene-related peptide concentrations in rats. Human Reproduction, 2000, 15, 949-953.	0.4	57
108	Increased Blood Pressure in Î±-Calcitonin Geneâ€“Related Peptide/Calcitonin Gene Knockout Mice. Hypertension, 2000, 35, 470-475.	1.3	141

#	Article	IF	Citations
109	Calcitonin gene-related peptide receptor expression in the neurons and glia of developing rat cerebellum: an autoradiographic and immunohistochemical analysis. Neuroscience, 2000, 100, 381-391.	1.1	33
110	Immunohistochemical localization of amylin in rat brainstemâ˜†,â˜†â˜†. Peptides, 2000, 21, 1743-1749.	1.2	22
111	Prevention and Treatment of Osteoporosis: Efficacy of Combination of Hormone Replacement Therapy with Other Antiresorptive Agents. Journal of Clinical Densitometry, 2000, 3, 187-201.	0.5	46
112	The mechanism of bone resorption by cyclosporin: involvement of the NO-cGMP pathway. Journal of Musculoskeletal Neuronal Interactions, 2000, 1, 141-3.	0.1	8
113	Regulation of Calcitonin Gene-Related Peptide Receptors in the Rat Uterus During Pregnancy and Labor and by Progesterone1. Biology of Reproduction, 1999, 61, 1023-1030.	1.2	29
114	Simulated weightlessness-induced attenuation of testosterone production may be responsible for bone loss. Endocrine, 1999, 10, 253-260.	2.2	45
115	Receptor for calcitonin gene-related peptide: localization in the dorsal and ventral spinal cord. Neuroscience, 1999, 92, 1389-1397.	1.1	50
116	Involvement of calcitonin geneâ€“related peptide in the modulation of human myometrial contractility during pregnancy. Journal of Clinical Investigation, 1999, 104, 559-565.	3.9	52
117	Uterine relaxation responses to calcitonin geneâ€“related peptide and calcitonin geneâ€“related peptide receptors decreased during labor in rats. American Journal of Obstetrics and Gynecology, 1998, 179, 497-506.	0.7	28
118	Calcitonin Gene-related Peptide (CGRP) is a Mediator of Vascular Adaptations During Hypertension in Pregnancy. Trends in Endocrinology and Metabolism, 1998, 9, 113-117.	3.1	13
119	A Four-Year Randomized Controlled Trial of Hormone Replacement and Bisphosphonate, Alone or in Combination, in Women with Postmenopausal Osteoporosis. American Journal of Medicine, 1998, 104, 219-226.	0.6	167
120	Prevention of Corticosteroid-Induced Bone Loss with Alendronate. Experimental Biology and Medicine, 1998, 217, 162-167.	1.1	26
121	Monoclonal antibodies reveal expression of the CGRP receptor in Purkinje cells, interneurons and astrocytes of rat cerebellar cortex. NeuroReport, 1998, 9, 3756-3759.	0.6	36
122	Pre-eclamptic toxemia: potential new therapy based on animal studies. Ceylon Medical Journal, 1998, 43, 138-46.	0.1	5
123	Calcitonin Gene-Related Peptide Is a Depressor in N ^G -Nitro- <scp>l</scp> -Arginine Methyl Ester-Induced Hypertension During Pregnancy. Hypertension, 1997, 29, 248-253.	1.3	68
124	Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone, 1997, 21, 275-280.	1.4	74
125	Progesterone up-regulates vasodilator effects of calcitonin geneâ€“related peptide in NG-nitro-l-arginine methyl esterâ€“induced hypertension. American Journal of Obstetrics and Gynecology, 1997, 176, 894-900.	0.7	36
126	Combined therapies with calcitonin and corticosteroids, or bisphosphonate, for treatment of hypercalcemia of malignancy. Journal of Bone and Mineral Metabolism, 1997, 15, 160-164.	1.3	5

#	Article	IF	Citations
127	Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily. Critical Reviews in Neurobiology, 1997, 11, 167-239.	3.3	397
128	Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone, 1996, 18, 301-304.	1.4	177
129	Calcitonin gene-related peptide reverses the hypertension and significantly decreases the fetal mortality in pre-eclampsia rats induced by NG-nitro-L-arginine methyl ester. Human Reproduction, 1996, 11, 895-899.	0.4	65
130	Calcitonin Gene-Related Peptide and Its Receptors: Molecular Genetics, Physiology, Pathophysiology, and Therapeutic Potentials. Endocrine Reviews, 1996, 17, 533-585.	8.9	470
131	Amylin-Immunoreactivity is Co-Stored in a Serotonin Cell Subpopulation of the Vertebrate Stomach and Duodenum.. Archives of Histology and Cytology, 1995, 58, 537-547.	0.2	19
132	Validation, role in perioperative assessment, and clinical applications of an immunoradiometric assay for human calcitonin. Peptides, 1995, 16, 307-312.	1.2	9
133	Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study. American Journal of Medicine, 1995, 99, 36-42.	0.6	149
134	In vivo central actions of rat amylin. Regulatory Peptides, 1995, 56, 167-174.	1.9	43
135	Mechanisms of the antihypertensive effects of dietary calcium and role of calcitonin gene related peptide in hypertension. Canadian Journal of Physiology and Pharmacology, 1995, 73, 981-985.	0.7	14
136	Comparative immunohistochemical distribution of amylin-like and calcitonin gene related peptide like immunoreactivity in the rat central nervous system. Canadian Journal of Physiology and Pharmacology, 1995, 73, 945-956.	0.7	47
137	Purification and biochemical characterization of neuropeptide Y2 receptor. Journal of Biological Chemistry, 1995, 270, 18523-30.	1.6	10
138	Oral pamidronate in refractory Paget's disease. Calcified Tissue International, 1994, 55, 240-240.	1.5	0
139	Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer, 1994, 73, 2223-2230.	2.0	71
140	Dramatic response to plicamycin in a patient with severe Paget's disease refractory to calcitonin and pamidronate. Seminars in Arthritis and Rheumatism, 1994, 23, 267.	1.6	10
141	Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Clinical Endocrinology, 1994, 41, 591-595.	1.2	30
142	Long- and short-term side effects and safety of calcitonin in man: A prospective study. Calcified Tissue International, 1993, 52, 90-93.	1.5	71
143	Pamidronate is effective for paget's disease of bone refractory to conventional therapy. Calcified Tissue International, 1993, 53, 237-241.	1.5	29
144	Comparative study of distribution and biochemical characterization of brain calcitonin gene-related peptide receptors in five different species. Neuroscience, 1993, 54, 513-519.	1.1	53

#	Article	IF	Citations
145	The effects of neonatal capsaicin on plasma levels and tissue contents of CGRP. Peptides, 1993, 14, 247-252.	1.2	33
146	Isolation, purification, and characterization of calcitonin gene-related peptide receptor. Peptides, 1993, 14, 691-699.	1.2	24
147	Antihypertensive Effects of Oral Calcium Supplementation May Be Mediated Through the Potent Vasodilator CGRP. American Journal of Hypertension, 1993, 6, 996-1002.	1.0	16
148	CGRP Radioreceptor assay: A new diagnostic tool for medullary thyroid carcinoma. Journal of Bone and Mineral Research, 1993, 8, 467-473.	3.1	13
149	Therapeutic success in severe iatrogenic osteoporosis in a young woman. Journal of the Royal Society of Medicine, 1993, 86, 117-8.	1.1	0
150	Sexually transmitted diseases in the age of AIDS. Ceylon Medical Journal, 1993, 38, 12-4.	0.1	0
151	Ocular irritative response to YAG laser capsulotomy in rabbits: Release of calcitonin gene-related peptide and effects of methysergide. Current Eye Research, 1992, 11, 307-314.	0.7	6
152	Age-related changes in tissue contents of immunoreactive calcitonin gene-related peptide. Aging Clinical and Experimental Research, 1992, 4, 211-217.	1.4	9
153	Involvement of multiple receptors in the biological effects of calcitonin geneâ€related peptide and amylin in rat and guineaâ€pig preparations. British Journal of Pharmacology, 1992, 107, 510-514.	2.7	53
154	Isolation, Purification, and Biochemical Characterization of Calcitonin Gene?Related Peptide Receptors. Annals of the New York Academy of Sciences, 1992, 657, 70-87.	1.8	23
155	Rapid publication: Hypocalcemic actions of amylin amide in humans. Journal of Bone and Mineral Research, 1992, 7, 1113-1116.	3.1	18
156	Multiple recurrent giant cell lesions associated with high circulating levels of parathyroid hormone-related peptide in a young adult. British Journal of Oral and Maxillofacial Surgery, 1991, 29, 102-105.	0.4	24
157	Anorexia following the intrahypothalamic administration of amylin. Brain Research, 1991, 539, 352-354.	1.1	169
158	Age-related increase of calcitonin gene-related peptide in rat thyroid and circulation. Peptides, 1991, 12, 1143-1147.	1.2	15
159	Circadian Variation of Plasma Calcitonin Gene-Related Peptide in Man. Journal of Neuroendocrinology, 1991, 3, 319-322.	1.2	12
160	Amylinâ€amide: a new boneâ€conserving peptide from the pancreas. Experimental Physiology, 1990, 75, 529-536.	0.9	58
161	AMYLIN AND AMYLIN-AMIDE LACK AN ACUTE EFFECT ON BLOOD GLUCOSE AND INSULIN. Journal of Endocrinology, 1990, 124, R9-R11.	1.2	47
162	Effects of in vivo stimulation on molecular forms of circulatory calcitonin and calcitonin gene-related peptide in man. Molecular and Cellular Endocrinology, 1990, 71, 13-19.	1.6	31

#	Article	IF	Citations
163	Isolation, purification and characterization of Î²-hCGRP from human spinal cord. Biochemical and Biophysical Research Communications, 1990, 167, 993-1000.	1.0	32
164	Calcitonin: Molecular Biology, Physiology, Pathophysiology and Its Therapeutic Uses. , 1990, , 121-160.		5
165	Both Î±- and Î²-calcitonin gene-related peptides are present in plasma, cerebrospinal fluid and spinal cord in man. Journal of Molecular Endocrinology, 1989, 3, 247-252.	1.1	31
166	Sensitive and Specific Radioreceptor Assay for Calcitonin Gene-Related Peptide. Journal of Neuroendocrinology, 1989, 1, 15-19.	1.2	17
167	In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit. Biochemical and Biophysical Research Communications, 1989, 162, 876-881.	1.0	121
168	Heterogeneity of plasma calcitonin gene-related peptide: Partial characterisation of immunoreactive forms. Peptides, 1988, 9, 407-410.	1.2	42
169	Calcitonin gene-related peptide and its specific binding sites in the cardiovascular system of rat. International Journal of Cardiology, 1988, 20, 29-37.	0.8	46
170	CALCITONIN FOR PREVENTION OF POSTMENOPAUSAL BONE LOSS. Lancet, The, 1988, 331, 900-902.	6.3	184
171	A sensitive and specific two-site enzyme-immunoassay for human calcitonin using monoclonal antibodies. Journal of Endocrinology, 1988, 119, 351-357.	1.2	26
172	Regional Distribution of Calcitonin Gene-Related Peptide and Its Specific Binding Sites in Rats with Particular Reference to the Nervous System. Neuroendocrinology, 1987, 46, 131-136.	1.2	105
173	THE PRESENCE OF CALCITONIN GENE-RELATED PEPTIDE IN HUMAN CEREBROSPINAL FLUID. Brain, 1987, 110, 1647-1655.	3.7	29
174	The origin of circulating calcitonin gene-related peptide in the rat. Journal of Endocrinology, 1986, 110, 185-190.	1.2	73
175	A new sensitive and fast peptide immunoassay based on enzyme amplification used in the determination of CGRP and the demonstration of its presence in the thyroid. Peptides, 1985, 6, 627-630.	1.2	16
176	CALCITONIN GENE-RELATED PEPTIDE: POTENT VASODILATOR AND MAJOR PRODUCT OF CALCITONIN GENE. Lancet, The, 1985, 326, 14-16.	6.3	170
177	Periodic paralysis complicating malaria. Postgraduate Medical Journal, 1981, 57, 273-274.	0.9	8
178	Calcitonin Gene-Related Peptide and Its Receptors: Molecular Genetics, Physiology, Pathophysiology, and Therapeutic Potentials. , 0, .		14